Targets › CHRNG
5 programs from 4 companies in 12 trials: 5 Phase 4, 5 Phase 2, 2 Phase 1; Other, Oncology, Respiratory; next expected readout Dec 2026.
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. (UniProt, P07510)
Open in Phaseline: the race on CHRNG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | ALA 10% gel Muscle-type nicotinic acetylcholine receptor antagonist | HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1 | Phase 4 | Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder … | Dec 2026 |
| The University of Texas Medical Branch, Galveston | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Post Operative Pulmonary Complications | Dec 2026 |
| Nordsjaellands Hospital | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Tracheal Intubation | Apr 2027 |
| The University of Texas Health Science Center, Houston | Suxamethonium Muscle-type nicotinic acetylcholine receptor agonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Anesthesia | – |
| Memorial Sloan Kettering Cancer Center | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 2 | Prostate Cancer | Jan 2027 |
Anesthesia (2) Post Operative Pulmonary Complications (1) Prostate Cancer (1) Tracheal Intubation (1) Cleft Lip and Palate (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Stimulant Use Disorder (1) Bipolar II Disorder (1) Bronchopulmonary Dysplasia (1) Onychomycosis of Toenail (1) Neuropsychiatric Syndromes (1)
small molecule (5)
The University of Texas Health Science Center, Houston (2) The University of Texas Medical Branch, Galveston (1) Memorial Sloan Kettering Cancer Center (1) Nordsjaellands Hospital (1)
CHRNA1 (5) CHRNB1 (5) CHRND (5) CHRNE (5) HCRTR2 (1) HCRTR1 (1) HTR2A (1) PTGS2 (1) PTGS1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.